Prurisol Trial "Between the subjects already en
Post# of 72433
![Avatar](/images/ProfileImages/398685088_3064_306524.png)
"Between the subjects already enrolled and those presently in screening, we have reached approximately 70% of theanticipated subjects. Subject recruitment was slower than projected due to competitive trials. In response, we have added additional investigator sites. The Company expects interim analysis top-line results in the third quarter of calendar 2017."
B-UP Trial
"Presently, three patients in the Cohort C, the 200mg dose, have completed their treatment."
Financial Status
"At March 31, 2017, we had $5.6 million in cash. We have expended substantial funds on the research and development of our product candidates."
"As of March 31, 2017, the available balance is approximately $16 million under this stock purchase agreement."
"We anticipate that future budget expenditures will be approximately $14 million over the next 12 months, including approximately $10 million for clinical trials."
Outstanding Shares
131,380,668
https://www.sec.gov/Archives/edgar/data/13552...ix_10q.htm
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)